BRNS — Barinthus Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $109.18m
- -$20.61m
- $0.80m
- 39
- 22
- 31
- 21
Annual cashflow statement for Barinthus Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22.7 | -17.9 | -51.1 | 5.32 | -73.4 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.744 | 4.74 | 24.9 | -15.4 | 14 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.93 | 1.96 | -6.84 | -4.31 | 6.17 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -18.7 | -11 | -32.6 | -14.4 | -50.9 |
| Capital Expenditures | -0.128 | -0.293 | -1.15 | -6.14 | -5.41 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.003 | — | -11.8 | 0.388 | 0 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.124 | -0.293 | -12.9 | -5.75 | -5.41 |
| Financing Cash Flow Items | 2.04 | 0.194 | -5.27 | 0 | -0.163 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.04 | 41.4 | 223 | 0.325 | 1.87 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -17.2 | 31.8 | 171 | -19.7 | -52.3 |